Heikki Joensuu
Finnish oncologist who treated the first GIST patient with imatinib in 2000 and led SSG XVIII, the trial that showed three years of adjuvant imatinib beats one year after surgery for high-risk GIST.
Overview
Heikki Joensuu is professor of oncology at Helsinki University Hospital. In 2001 he reported the first patient with metastatic gastrointestinal stromal tumour treated with imatinib, opening the era of targeted therapy for the disease. He was first author of the 2012 JAMA report of the Scandinavian Sarcoma Group XVIII trial, which showed that three years of adjuvant imatinib improved recurrence-free and overall survival compared with one year in high-risk resected GIST, now the standard. He has also led adjuvant trastuzumab trials in breast cancer.
Similar pages
not linked directly; found by shared links- PersonMichael C. Heinrich
Shares KIT exon 11-mutant GIST, Gastrointestinal stromal tumour (GIST), Sarcomas (soft tissue, bone, GIST) and the tags gist, trialist.
- PersonSebastian Bauer
Shares Gastrointestinal stromal tumour (GIST), Sarcomas (soft tissue, bone, GIST) and the tags gist, trialist.
- PersonGeorge D. Demetri
Shares Gastrointestinal stromal tumour (GIST), Sarcomas (soft tissue, bone, GIST) and the tag gist.
- PersonPiotr Rutkowski
Shares Gastrointestinal stromal tumour (GIST), Sarcomas (soft tissue, bone, GIST) and the tag trialist.
- PersonWilliam D. Tap
Shares Sarcomas (soft tissue, bone, GIST) and the tag trialist.
- PersonRobin L. Jones
Shares Sarcomas (soft tissue, bone, GIST) and the tag trialist.
- PersonPatrick Schöffski
Shares Sarcomas (soft tissue, bone, GIST) and the tag trialist.
- PersonPatricia Pautier
Shares Sarcomas (soft tissue, bone, GIST) and the tag trialist.